The activities of this specialized group are divided into three main research topics:

– Development of innovative and sustainable drug delivery systems (DDS) and technologies, to be used in theprevention of diseases and optimization of treatments (cosmetics, medical devices and medicines);

– Characterization of the target quality product;

– Safe and efficacy studies – from lab to society.

Overview:

The Pharmaceutical Development Lab aims to unravel new relevant drug delivery system strategies with the ability to make a difference in the promotion of a healthy society.

Areas of interest:

Develop 3D systems, as tailored-made drug delivery systems, using assisted Quality by Design (QbD) approaches.

This project uses 3D printing to produce individualized drug load treatment platforms, adapted in shape and size to the patient.

This technology will repurpose the current therapeutic systems available on the market by modulating the drug release through advanced printing strategies.

Advanced Topical Drug Delivery Systems (DDS) in Skin Diseases and in Skin Health.

These projects are dedicated to developing novel DDS for skin delivery and targeting, with improved safety and efficacy, while minimizing side effects.

Projects with established drugs and substances have been performed, taking advantage of its ease of use, speed, accessibility, and sustainability.

Individualized Drug Delivery Systems (DDS) – From design to clinic:

The group is highly involved with the pharmaceutical industry and national hospitals, to ensure that the new developed products will be translated into healthcare pathways.

Quality Characteristics of Topical Medicinal products through its marketing life cycle.

The group has access to characterization tools that facilitate the management of the product’s life cycle, by monitoring its microstructure/physical properties, which are crucial for the product performance and usability.

Safe and efficacy studies – from lab to society: Clinical assessment of safety and efficacy of products/technologies, in accordance with national and international regulatory requirements, to allow the appropriate translation of academic research into people-centered healthcare.